

29 Jan 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: Bayer's pipeline refresh; J&J's selective pharma M&A approach; silver lining for Gilead's Trodelvy miss?; paying for obesity drugs; and the story behind Vertex and CRISPR's gene therapy breakthrough.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 26 January 2024, including: Bayer's pipeline refresh; J&J's selective pharma M&A approach; silver lining for Gilead's Trodelvy miss?; paying for obesity drugs; and the story behind Vertex and CRISPR's gene therapy breakthrough.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Bayer's Pipeline Refresh Focuses On Early Stage Despite Near-Term Growth Needs](#)" - *Scrip*, 18 Jan, 2024.)

(Also see "[J&J Has An Appetite For Pharma M&A, But Knows What It Likes](#)" - *Scrip*, 23 Jan, 2024.)

(Also see "[Do The Dark Clouds Over Gilead's Trodelvy Have A Silver Lining?](#)" - *Scrip*, 22 Jan, 2024.)

(Also see "[Paying For Obesity Drugs: The Looming Affordability Crisis](#)" - *Scrip*, 19 Jan, 2024.)

(Also see "[CRISPR Therapeutics And Vertex's CRISPR Breakthrough: How And Why They Got There First](#)" - *Scrip*, 19 Jan, 2024.)

[Click here to explore this interactive content online](#) 